Recommendations emphasize collaborative efforts and tailored treatments for prostate cancer, suggesting improved outcomes.
Key Points
Maximizing local control can prevent biochemical recurrence in prostate cancer patients, ensuring better outcomes.
Assessment of BRCA mutations is crucial for understanding familial risk and informing treatment decisions in metastatic castration-resistant prostate cancer.
A multidisciplinary approach should be standard to enhance patient care and adherence to active surveillance in low-risk prostate cancer groups.
Geriatric assessment is vital for tailoring treatments in older prostate cancer patients, addressing their unique health needs.